Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA

Contacts of persons infected with multidrug-resistant tuberculosis (MDR TB) have few prophylaxis options. Of 50 contacts of HIV- and MDR TB-positive persons who were treated with moxifloxacin, 30 completed treatment and 3 discontinued treatment because of gastrointestinal symptoms. Moxifloxacin was...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases 2015-03, Vol.21 (3), p.500-503
Main Authors: Trieu, Lisa, Proops, Douglas C, Ahuja, Shama D
Format: Article
Language:English
Subjects:
antibiotic
Antibiotic Prophylaxis
antimicrobials
Antitubercular agents
Antitubercular Agents - therapeutic use
Care and treatment
Coinfection
contact tracing
Dispatch
Drug resistance
fluoroquinolones
Fluoroquinolones - therapeutic use
Follow-Up Studies
HIV Infections
Humans
Moxifloxacin
Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA
Mycobacterium tuberculosis
New York City - epidemiology
Prophylaxis
Treatment Outcome
tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - epidemiology
Tuberculosis, Multidrug-Resistant - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Contacts of persons infected with multidrug-resistant tuberculosis (MDR TB) have few prophylaxis options. Of 50 contacts of HIV- and MDR TB-positive persons who were treated with moxifloxacin, 30 completed treatment and 3 discontinued treatment because of gastrointestinal symptoms. Moxifloxacin was generally well-tolerated; further research of its efficacy against MDR TB is needed.
ISSN:1080-6040
1080-6059
DOI:10.3201/eid2103.141313